Medical CBRN Defense Consortium – Rapid Response Monoclonal Antibody (mAb) Platform System for Accelerated Development of a Prototype mAb MCM against a Biodefense Threat of Interest

This is not a Request for Prototype Proposals, but for planning purposes only. A project award will not be awarded from this announcement. The Government intends to announce one Request for Prototype Proposals (RPP 18-08) for execution of a project award(s) in support of Medical Countermeasure Systems Research and Development related to specified project requirements. The purpose of this announcement is to provide members of the Medical CBRN Defense Consortium, and industry in general, advanced notification of Government intent.
On 08 April 2016, the Government entered into an Other Transaction Agreement (OTA) with one (1) consortium, the Medical CBRN Defense Consortium (MCDC), in support of Medical Countermeasure Systems related research and development prototype projects. It is the intent of the Government to make project award(s) to member(s) of the MCDC as a result of member project proposals submitted via the Request for Prototype Proposals process.

RPP 18-08

The Government anticipates one (1) projects for white papers and full proposals to be solicited via W15QKN-16-9-1002 – consisting of the following:

• Development and Utilization of a Rapid Response Monoclonal Antibody (mAb) Platform System for Accelerated Development of a Prototype mAb MCM against a Biodefense Threat of Interest.

In order to obtain more information regarding the above projects, you must be a member of the Medical CBRN Defense Consortium (MCDC), www.medcbrn.org. For more information regarding membership or general questions to the MCDC, contact Michael Stebbins, at 843-760-4094 or mcdc@ati.org.